RLMD - Relmada making changes to phase 3 depression candidate trial
2023-03-24 14:28:18 ET
- Relmada Therapeutics ( NASDAQ: RLMD ) is making "critical changes" to a phase 3 trial of REL-1017 as an adjunct treatment for major depressive disorder.
- The changes are being made to the Reliance II trial, the second of two late-stage trials.
- The stock is down ~6% in Friday afternoon trading.
- Reliance I missed its primary endpoint .
- Though the company didn't specify what the changes for Reliance II are, it did say a protocol amendment has been finalized and is ready for implementation.
- Relmada ( RLMD ) is also going to begin another phase 3 trial around mid year.
- Seeking Alpha has viewed Relmada ( RLMD ) as a strong sell since Oct. 20, 2022.
For further details see:
Relmada making changes to phase 3 depression candidate trial